Abeona therapeutics reinitiates enrollment in eb-101 pivotal phase 3 viital™ study in rdeb after covid-19 related pause and announces progress in patient enrollment in mps iii studies

New york and cleveland, july 08, 2020 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical programs, highlighted by the restart of patient enrollment in the company’s pivotal phase 3 viital™ study of eb-101, its autologous, gene-corrected cell therapy, for the treatment of recessive dystrophic epidermolysis bullosa (rdeb). enrollment in the viital™ study at stanford university medical center was paused in march 2020 in order to redirect healthcare resources to covid-19 patients and to ensure the safety of study participants and site staff.
ABEO Ratings Summary
ABEO Quant Ranking